Xeris Pharmaceuticals (NASDAQ: XERS) — Perfil da empresa, notícias e dados financeiros
Xeris Pharmaceuticals develops innovative therapies in endocrinology and neurology using proprietary formulation technologies for better patient care.
Xeris Pharmaceuticals
Xeris Pharmaceuticals (NASDAQ:XERS) is engaged in developing and commercializing innovative therapies in endocrinology and neurology. The company focuses on creating products that use its proprietary formulation technology platforms, including XeriSol™ and XeriJect™, which are designed to enhance the efficacy, safety, and convenience of therapies for patients with serious and chronic medical conditions. Xeris Pharmaceuticals aims to address significant unmet medical needs by bringing to market treatments that offer better clinical outcomes and more accessible patient care. Its portfolio includes Gvoke® for severe hypoglycemia in diabetes patients, reflecting the company's commitment to improving the lives of those living with challenging medical conditions. Through ongoing research and development, Xeris seeks to expand its product offerings and deliver innovative healthcare solutions worldwide.
Resumo
Operações
Produtos e/ou serviços de Xeris Pharmaceuticals
- Gvoke HypoPen and PFS, a ready-to-use, room-temperature stable liquid glucagon for severe hypoglycemia.
- Recorlev (levoketoconazole), a cortisol synthesis inhibitor for endogenous Cushing’s syndrome treatment.
- Keveyis (dichlorphenamide), the first FDA-approved drug for primary hyperkalemic and hypokalemic periodic paralysis.
- XeriJect technology, focusing on formulation technology for injectable and infusible drug candidates.
- Self-administered glucagon for exercise-induced hypoglycemia, offering a convenient option for individuals with diabetes.
- A pipeline of developmental programs targeting endocrine disorders, leveraging novel delivery technologies for better patient care.
equipe executiva do Xeris Pharmaceuticals
- John P. ShannonChairman & CEO
- Kevin McCullochPresident & COO
- Steven M. PieperChief Financial Officer
- Beth P. HechtChief Legal Officer & Corporate Secretary
- Anh T. NguyenChief Medical Officer
- Brian ConnerSVP of Quality and Chief Compliance & Risk Officer
- Kendal KorteSenior Vice President of Human Resources
- Joshua BennettVice President of Strategy & Business Development
Últimas notícias sobre a Xeris Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Xeris Pharmaceuticals, em USD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 335,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -5.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 291,8 mi | 24,9 mi | 554 mil | |
| 203,1 mi | -33,6 mi | -54,8 mi | |
| 163,9 mi | -44 mi | -62,3 mi | |
| 110,2 mi | -81,9 mi | -94,7 mi |